LCTX Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Alameda, CA.
Company profile
Ticker
LCTX
Exchange
Website
CEO
Brian M. Culley
Employees
Incorporated in
Location
Fiscal year end
Sector
Industry (SEC)
Amgen • Biogen • Gilead Sciences • Qiagen • Moderna • BioNTech SE • Enzon Pharmaceuticals • Denali Therapeutics • Allogene Therapeutics • Innate Pharma ...
Former names
Biotime Inc
SEC CIK
Corporate docs
IRS number
943127919
LCTX stock data
()
Investment data
Securities sold
Number of investors
Calendar
7 May 20
10 Jul 20
31 Dec 20
News
Company financial data Financial data
| Quarter (USD) | Mar 20 | Dec 19 | Sep 19 | Jun 19 | |
|---|---|---|---|---|---|
| Revenue | 514K | 1.24M | 567K | 779K | |
| Net income | -8.43M | -4.56M | -16.52M | -30.05M | |
| Diluted EPS | -0.06 | -0.11 | -0.2 | ||
| Net profit margin | -1640% | -367% | -2913% | -3858% | |
| Operating income | -7.44M | -6.87M | -8.42M | -10.82M | |
| Net change in cash | 335K | -4.87M | 6.16M | -9.8M | |
| Cash on hand | 9.83M | 9.5M | 14.37M | 8.21M | |
| Cost of revenue | 94K | 123K | 114K | 107K |
| Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
|---|---|---|---|---|---|
| Revenue | 3.52M | 4.99M | 3.46M | 5.92M | |
| Net income | -11.83M | -46.78M | -23.29M | 18.62M | |
| Diluted EPS | -0.08 | -0.36 | -0.17 | 0.34 | |
| Net profit margin | -336% | -938% | -673% | 314% | |
| Operating income | -38.88M | -41.8M | -38.9M | -58.97M | |
| Net change in cash | -14.09M | -13.25M | 14.75M | -20.14M | |
| Cash on hand | 9.5M | 23.59M | 36.84M | 22.09M | |
| Cost of revenue | 412K | 302K | 168K | 358K |
Financial data from company earnings reports
Recent insider trades
| Date | Owner | Security | Transaction | Code | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|
| 1 Jul 20 | Russell Angus C. | Stock Option Common Shares | Grant | Aquire A | No | 0.8263 | 40,000 | 33.05K | 40,000 |
| 1 Jul 20 | Bailey Don M | Stock Option Common Shares | Grant | Aquire A | No | 0.8263 | 40,000 | 33.05K | 40,000 |
| 1 Jul 20 | Andrews Deborah J | Stock Option Common Shares | Grant | Aquire A | No | 0.8263 | 40,000 | 33.05K | 40,000 |
| 1 Jul 20 | Mulroy Michael H. | Stock Option Common Shares | Grant | Aquire A | No | 0.8263 | 40,000 | 33.05K | 40,000 |
| 1 Jul 20 | Farrell Stephen C | Stock Option Common Shares | Grant | Aquire A | No | 0.8263 | 40,000 | 33.05K | 40,000 |
Institutional ownership Q1 2020
13F holders |
Current |
|---|---|
| Total holders | 2 |
| Opened positions | 1 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
13F shares |
Current |
|---|---|
| Total value | 0 |
| Total shares | 0 |
| Total puts | 0 |
| Total calls | 0 |
| Total put/call ratio | – |
Largest owners |
Shares | Value |
|---|---|---|
| Proequities | 0 | $0 |
| IFP Advisors | 0 | $0 |
Financial report summary
?Competition
Intellicell Biosciences • International Stem Cell • Astellas Pharma • IVERIC bio • VistaGen Therapeutics • Astellas Pharma • Biostage • RPE
Content analysis
?
| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. junior Avg
|
|
New words:
abidance, abide, abroad, absolute, abuse, ACA, accuracy, accurate, accurately, activist, acuity, adhere, adhered, Advantage, advisory, afford, Affordable, afforded, agency, agenda, ahead, alia, allotted, altogether, amelioration, amenable, Amsterdam, announce, announced, antitrust, asterisk, attain, attempt, attempting, attract, attracting, augment, automate, averse, avoid, back, backup, bank, barring, beneficiary, billion, binding, biologic, biosimilar, blank, Blueprint, branded, breadth, Brexit, Brian, bribery, bring, broad, broadly, budget, bulk, burdensome, calling, capability, capacity, care, carefully, catastrophic, caution, central, centralized, certainty, certification, certiorari, cessation, chain, characterized, chemical, China, choose, choosing, Circuit, circumvent, civil, CMS, Code, codified, committed, commonly, compel, compete, competing, complex, complexity, complicating, composition, compromised, concentration, concluded, confidence, confidential, confidentiality, Conformit, congressional, consecutive, consent, consign, constrain, consuming, contact, contest, convenience, Convention, correspondingly, corroborated, Corrupt, counterparty, country, coverage, criminal, CRT, cryopreserved, CTOA, Culley, cybersecurity, damage, damaging, database, dealing, decided, deciding, declared, defraud, degree, demand, demonstrate, demonstrated, denial, deployment, deprive, destructive, deter, deteriorating, deterring, difficult, difficulty, disagree, discontinue, discontinued, disgorgement, dispensed, disrupt, disrupted, disruption, distancing, distraction, District, diversion, divert, diverting, divulged, domestic, donated, dosed, double, downgrade, drop, dropping, duration, ease, educate, education, effectuated, efficacy, electorate, electrical, eligibility, eligible, EMA, embryonic, enacted, encounter, engineering, enlist, enterprise, entirety, entry, environmental, EPC, epithelial, equivalent, espionage, essence, ethical, eventual, eventually, evolve, evolving, exceed, excessive, exemption, exhausted, expand, expanded, experimental, expertise, expiry, exploit, exploitation, exploiting, export, expose, extraction, extraordinary, extreme, eye, face, faced, facilitating, facing, factual, fail, failed, failing, fall, false, family, feedback, field, firm, fluid, foreseeable, forgivable, forgiven, forgo, formal, formally, formulary, forum, forward, fraud, fraudulent, frequency, furlough, global, globally, group, growing, guarantee, guaranteed, Gyroscope, Hadassah, healthcare, heavily, heightened, heightening, hematopoietic, hEPC, HHS, high, higher, HIPAA, HITECH, hour, hydrogel, IA, identical, imaging, immature, impede, impermissible, implanted, imposition, imprisonment, improper, improperly, inability, inaccurate, inadvertent, inappropriate, incentivize, inclined, inconclusive, incorrect, increasingly, IND, indirectly, induce, infrastructure, infused, inhaled, injured, insecurity, insolvency, inspection, instability, instance, instilled, insufficient, intense, intensity, inter, internationally, interruption, intraperiod, introduction, invalid, inventory, investigation, investigational, investigator, IP, IRB, IRC, isolating, jeopardized, Judge, judicial, Justice, justify, Kingdom, knowable, knowingly, label, labeled, labeling, labor, larger, lawfully, leave, left, legislation, legislative, length, lengthy, lessen, licensor, licensure, lifted, light, literature, lived, loan, local, London, lose, lost, lot, low, lump, magnitude, malware, mandate, mandatory, master, matter, maximize, meaningful, Medicaid, Medicare, methodology, milestone, misappropriation, miscalculated, misinterpreted, misperception, misstatement, misuse, monitor, monitoring, moved, multinational, mutual, narrower, NDA, neural, newly, noncompetitive, Obama, obsolete, Ocata, older, ophthalmic, opportunity, opposition, oral, orderly, Organization, organized, orin, otherin, outbreak, outlined, output, outsource, outsourced, outweigh, oversee, overseeing, oversight, pace, pandemic, parthenogenetically, passed, Patch, pause, paused, Paycheck, payor, penalty, percent, perception, permanently, permissible, permission, persistence, personal, pertinent, Pharma, pharmaceutical, pharmacy, photoreceptor, physical, Physician, plaintiff, political, poor, population, Portability, potency, poverty, PPP, preclinical, prescription, preserve, President, pressure, prevalence, prevalent, prevent, prevented, preventing, prevention, priority, privacy, procedure, profile, prohibit, prolonged, promising, promotion, promotional, propagation, proper, properly, proportion, prosecution, proven, publish, published, punishable, purification, purifying, purity, pursuit, purview, quality, quantity, ransomware, rapid, rapidly, raw, reach, reached, reallocate, reallocated, reallocation, rebate, recall, recipient, recommendation, recover, redemption, referendum, referral, refinement, regeneration, regime, registered, reinvesting, relationship, Relief, relinquish, remanded, removing, remuneration, repaid, repeal, repealed, repeated, reproductive, reputation, reputational, requested, rescission, reserved, residence, resorbable, resource, responding, restructuring, retail, retina, retroactive, reveal, revoked, RPE, RSU, safer, safety, satisfactory, satisfy, SBA, scale, scheme, scientific, SCRO, scrutiny, secret, seizure, sensitive, sequester, serialization, setback, shelter, shipment, shipping, shorten, shut, shutdown, side, signature, similarly, simultaneously, Singapore, site, slower, social, solicitation, solicited, soliciting, sophisticated, sophistication, specialty, speculative, spread, stability, stable, staffing, statute, step, stop, store, stored, strain, strategic, strategy, strict, stringent, study, subcontract, sublease, sublicensing, submission, succeed, suggested, suitable, Sunshine, supply, Supreme, surgical, surveillance, susceptible, sustain, system, systemic, tariff, taxation, Taxpayer, teaching, team, technical, telecommunication, temporarily, terrorism, thereunder, threaten, threatened, titled, tolerated, topline, toxicology, track, tracking, transmission, transmit, transparency, transport, transportation, Trump, turn, unannounced, unanticipated, unauthorized, unclear, uncommon, unconstitutional, uncured, undertook, undetected, unexpected, unforeseen, uniform, Union, University, unlawful, unrelated, unrest, unstable, unsuccessful, unused, upheld, user, validity, valuable, variety, verification, verify, viable, video, violate, violation, visibility, visual, vitro, vivo, voluntary, vulnerable, wage, war, weigh, whatsoever, whichever, wholesale, wide, widely, willfully, withdraw, withdrawal, worldwide, writing, wrong, Wuhan, yearly, yield
Removed:
added, advertisement, aging, Ascendance, assisted, biology, CAL, capitalized, cellular, Chairman, clearance, comprising, controlling, description, distributed, dossier, effected, endpoint, engraftment, exceeded, expended, expensed, expired, explain, finalize, focused, formulation, freestanding, functional, generating, heart, hemifacial, immortality, integrating, investee, issuer, Kingsley, lab, LifeMap, lipotransfer, muscle, nonconsolidated, nonemployee, OrthoCyte, owner, photographic, pivotal, recording, retention, reversed, science, text, transferring, treated, unaffiliated, unilaterally, volumetric
Financial reports
10-Q
2020 Q1
Quarterly report
7 May 20
10-K/A
2019 FY
Annual report (amended)
28 Apr 20
10-K
2019 FY
Annual report
12 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
8 Aug 19
10-Q
2019 Q1
Quarterly report
9 May 19
10-K/A
2018 FY
Annual report (amended)
1 May 19
10-K/A
2018 FY
Annual report (amended)
30 Apr 19
10-K
2018 FY
Annual report
14 Mar 19
10-Q
2018 Q3
Quarterly report
8 Nov 18
Current reports
8-K
Other Events
21 May 20
8-K
Lineage Cell Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
7 May 20
8-K
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
12 Mar 20
8-K
Regulation FD Disclosure
13 Jan 20
8-K
Financial Results AND PROVIDES BUSINESS UPDATE
12 Nov 19
8-K
Other Events
18 Oct 19
8-K
Lineage Cell Therapeuticspresents New Opregen®data at American Academy of Ophthalmology Annual Meeting
15 Oct 19
8-K
Other Events
19 Sep 19
8-K
Amendments to Articles of Incorporation or Bylaws
12 Aug 19
8-K
Results of Operations and Financial Condition
8 Aug 19
Registration and prospectus
S-3
Shelf registration
1 May 20
S-8
Registration of securities for employees
8 Aug 19
425
Business combination disclosure
1 Mar 19
424B3
Prospectus supplement
4 Feb 19
S-4/A
Registration of securities issued in business combination transactions (amended)
14 Jan 19
S-4
Registration of securities issued in business combination transactions
4 Jan 19
425
Business combination disclosure
6 Dec 18
425
Business combination disclosure
6 Dec 18
425
Business combination disclosure
9 Nov 18
425
Business combination disclosure
8 Nov 18
Proxies
DEFA14A
Additional proxy soliciting materials
14 Jun 19
DEF 14A
Definitive proxy
14 Jun 19
DEF 14A
Definitive proxy
29 Mar 18
DEFA14A
Additional proxy soliciting materials
29 Mar 18
PRE 14A
Preliminary proxy
19 Mar 18
DEFR14A
Revised proxy
13 Jul 17
DEFA14A
Additional proxy soliciting materials
30 Jun 17
PRER14A
Preliminary revised proxy
30 Jun 17
DEFA14A
Additional proxy soliciting materials
3 May 17
DEF 14A
Definitive proxy
1 May 17
Other
EFFECT
Notice of effectiveness
11 May 20
CORRESP
Correspondence with SEC
6 May 20
UPLOAD
Letter from SEC
6 May 20
CT ORDER
Confidential treatment order
14 Dec 17
CT ORDER
Confidential treatment order
12 Sep 17
EFFECT
Notice of effectiveness
28 Jun 17
CORRESP
Correspondence with SEC
27 Jun 17
UPLOAD
Letter from SEC
22 Jun 17
EFFECT
Notice of effectiveness
5 May 17
CORRESP
Correspondence with SEC
3 May 17
Ownership
4
Lineage Cell Therapeutics / NEAL C BRADSHER ownership change
2 Jul 20
4
Lineage Cell Therapeutics / Brian M Culley ownership change
2 Jul 20
4
Lineage Cell Therapeutics / STEPHEN C FARRELL ownership change
2 Jul 20
4
Lineage Cell Therapeutics / Michael H. Mulroy ownership change
2 Jul 20
4
Lineage Cell Therapeutics / DON M BAILEY ownership change
2 Jul 20
4
Lineage Cell Therapeutics / DEBORAH J ANDREWS ownership change
2 Jul 20
4
Lineage Cell Therapeutics / Angus C. Russell ownership change
2 Jul 20
4
Lineage Cell Therapeutics / ALFRED D KINGSLEY ownership change
2 Jul 20
SC 13D/A
OncoCyte / Lineage Cell Therapeutics ownership change
27 Apr 20
4
Lineage Cell Therapeutics / Brian M Culley ownership change
1 Apr 20
Patents
APP
Utility
Methods for Differentiating Pluripotent Stem Cells In Dynamic Suspension Culture
19 Mar 20
Methods for differentiating pluripotent stem cells to neuroectoderm in dynamic suspension culture using small molecule or protein inhibitors of TGFβ/Activin/Nodal signaling and BMP signaling are provided.
APP
Utility
Methods for Measuring Therapeutic Effects of Retinal Disease Therapies
19 Mar 20
Described herein are compositions and methods for treating retinal diseases or disorders using RPE cells.